$ cat ./records/gates-foundation-commits-180-million-for-global-cervical-cancer-e-2024.txt
Gates Foundation Commits $180 Million for Global Cervical Cancer Elimination and HPV Vaccine Scale-Up
[RECORD.TXT] · cat --full
At the World Cervical Cancer Forum in March 2024, the Gates Foundation announced a commitment of up to $180 million toward cervical cancer elimination, including $100 million for HPV vaccination and $80 million for HPV vaccine research. The pledge was part of nearly $600 million in new global commitments. Cervical cancer kills more than 340,000 women annually, with 90 percent of deaths in low- and middle-income countries, and is preventable with two doses of HPV vaccine before sexual debut.
Free forever · No ads · Solo developer
If this was worth a read, help make the next entry possible.
Every entry in this archive was researched, verified, and written by one person — for free. No corporate funding. No ad revenue. Just a developer who believes verified history should be accessible to everyone. Your donation directly funds new entries.
Crypto accepted · No subscription required
← Previous
Gates Foundation Awards $3.87 Million to Pairwise and IITA for CRISPR Gene-Edited Yam in Nigeria
Next →
Breakthrough Energy Ventures Raises $839 Million Fund III with Food and Agriculture Focus
[CROSS_REFERENCES] · grep --category='Global Health'
Related Accomplishments
January 2026
Gates-backed World Mosquito Program reaches 16 million people protected from dengue via Wolbachia method
The World Mosquito Program — backed in part by the Gates Foundation — announced in January 2026 that its Wolbachia-infected mosquito releases had reached over 16.1 million people across multiple countries, including Colombia, Indonesia, Brazil, Sri Lanka, Fiji, Vanuatu, and Vietnam. Wolbachia-carrying Aedes aegypti mosquitoes — which block dengue, Zika, chikungunya, and yellow fever transmission — had established self-sustaining populations in treated cities without requiring ongoing releases. Gold-standard randomised trials in Indonesia showed a 77% reduction in dengue incidence. The program represented one of the largest and most cost-effective vector control deployments in history.
2025
Gates-Funded Monoclonal Antibody Shows Early Promise as a Single-Shot Malaria Shield
[ARCHIVE_FUNDING] · INDEPENDENT · NO ADS
One developer. >300 verified entries. Zero ads. Forever free.
No sponsors, no paywall, no algorithm. If this archive has been useful to you, reader support is what keeps it running.